tiprankstipranks
Advertisement
Advertisement
MapLight Therapeutics downgraded to Neutral from Buy at UBS
PremiumThe FlyMapLight Therapeutics downgraded to Neutral from Buy at UBS
16d ago
MapLight Therapeutics downgraded to Neutral from Buy at UBS
Premium
The Fly
MapLight Therapeutics downgraded to Neutral from Buy at UBS
16d ago
MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
Premium
The Fly
MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum
29d ago
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
PremiumRatingsAnalyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target on Favorable Risk‑Reward and Alzheimer’s Pipeline Upside
30d ago
Video: Jefferies more bullish on Ford and GM
Premium
The Fly
Video: Jefferies more bullish on Ford and GM
30d ago
Morning Movers: Ensign Group surges following second quarter results
Premium
The Fly
Morning Movers: Ensign Group surges following second quarter results
30d ago
MapLight Therapeutics price target raised to $52 from $48 at UBS
PremiumThe FlyMapLight Therapeutics price target raised to $52 from $48 at UBS
1M ago
BMO starts MapLight at Outperform, eyes validation data in August
Premium
The Fly
BMO starts MapLight at Outperform, eyes validation data in August
1M ago
MapLight Therapeutics initiated with an Outperform at BMO Capital
Premium
The Fly
MapLight Therapeutics initiated with an Outperform at BMO Capital
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100